Compare OSUR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSUR | ACIU |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 275.4M | 229.0M |
| IPO Year | 2000 | 2015 |
| Metric | OSUR | ACIU |
|---|---|---|
| Price | $4.19 | $2.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.00 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 818.8K | 290.6K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $167,064,000.00 | N/A |
| Revenue This Year | $4.48 | $706.75 |
| Revenue Next Year | $7.76 | $321.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.08 | $1.65 |
| 52 Week High | $4.33 | $4.00 |
| Indicator | OSUR | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 31.71 |
| Support Level | $2.80 | $2.03 |
| Resistance Level | $4.33 | $3.92 |
| Average True Range (ATR) | 0.25 | 0.16 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 90.87 | 12.83 |
OraSure Technologies Inc is principally engaged in the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions. It develops products and services that support diagnostic testing and healthcare data analysis, with a focus on improving access to healthcare. The company derives its revenues from the sale of diagnostics products and sample management solutions. Geographically, it generates the maximum revenue from the United States.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.